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natriuretic peptides have not been previously reported.Methods A total of 1,445 patients attending the emergency department with acute dyspnea had measurements taken of
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of HF. The diagnostic performance of all three peptides is impaired by AF. This warrants consideration of adjusted
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193syncope. AF may cause or complicate HF and establishing
the presence or absence of HF in dyspneic patients with AF
may be challenging. The B type cardiac peptides are estab-
lished as aids to the diagnosis of HF in patients presenting
to the ED with recent onset dyspnea (7,8). AF, a frequent
comorbidity in HF, disturbs plasma B-type natriuretic
peptide (BNP) and amino terminal pro-B-type natriuretic
peptide (NT-proBNP) (9–13) and may impair their per-
formance in the diagnosis of HF (9,10).
The stable hormone fragment of atrial natriuretic peptide
(MR-proANP) has similar utility in diagnosing HF as the B
type peptides (14,15). We assessed the effect of AF on the
diagnostic performance of MR-proANP, in comparison to
BNP and NT-proBNP, in patients enrolled in the BACH
(Biomarkers in Acute Heart Failure) trial.
Methods
As previously described, the BACH trial was a prospective,
15-center international study of patients presenting to the
ED with acute dyspnea (15). Results indicated non-
inferiority for MR-proANP for diagnosis of HF. Data for
rhythm (according to electrocardiography [ECG] on
recruitment; available in 1,445 cases), biomarkers (BNP,
NT-proBNP and MR-proANP), and outcome were avail-
able in 1445 of 1641patients recruited to the BACH trial.
Study population. This study was approved by the review
boards of the enrolling institutions. Patients from 15 centers
(8 in the United States, 6 in Europe, and 1 in New Zealand)
were enrolled from March 2007 to February 2008. Patients
reporting shortness of breath as their primary complaint
upon presentation to the ED were eligible. Patients under
18 years, unable to provide consent, suffering acute ST-
segment elevation myocardial infarction or receiving renal
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Two cardiologists independently
reviewed medical records and
classified the diagnoses as HF,
pneumonia or another cause of
dyspnea. They were blinded
to each other’s assessments,
the investigational markers, and
the emergency physician’s pre-
liminary diagnosis. They had
access to the ED case report
forms including medical history
plus data on chest radiography,
radionuclide angiography, echo-
cardiography, and cardiac cath-
eterization as available, as well
as the hospital course for those
who were admitted. In the event of diagnostic disagree-
ment between reviewers they were asked to come to
a consensus failing which a third cardiology adjudicator
was assigned by the endpoints committee to determine
a final diagnosis. All-cause mortality was recorded to 90
days of follow-up.
Measurement of biomarkers. Blood samples were
collected into EDTA, and plasma was stored at 70C in
plastic freezer vials. MR-proANP was measured with an
automated sandwich chemiluminescence immunoassay on
the Kryptor System (BRAHMS AG, Hennigsdorf Berlin,
Germany) at the University of Maryland School of Medi-
cine. The assay is described in detail elsewhere (14) and has
been used in other studies (16–19). In this laboratory, the
MR-proANP assay had a limit of quantitation of 4.5 pmol/l,
a within-run imprecision of 1.2%, and total imprecision
(CV) of 5.4%.
BNP was measured with Triage two-site immunoassay
reagents (Biosite, San Diego, California) formatted for
Beckman Coulter instrumentation (Brea, California). The
limit of quantitation was 5.0 ng/l, within-run imprecision
was 1.5%, and total imprecision (CV) was 3.0%.
NT-proBNP was measured by electrochemiluminescence
with the ElecSys 2010 analyzer (Roche Diagnostics, Indi-
anapolis, Indiana). Limit of quantitation was 10.0 ng/l,
within run imprecision 1.5% and total imprecision (CV) of
3.0%. All samples were processed by personnel blind to
patient data.
Statistical analysis. Values are expressed as mean  SD,
medians and quartiles, or counts and percentages as appro-
priate. Diagnostic groups were compared with independent-
samples t-tests and chi-square tests as appropriate. The
discriminative power of each peptide for the diagnosis of HF
was analysed separately for AF and non AF patients by
receiver-operator curve (ROC) analyses. Cut points were
determined by maximizing the product of sensitivity and
specificity. Secondary analyses utilized logistic and Cox
regressions and survival curves plotted by the Kaplan-Meier
method and compared with log rank tests. Multivariate
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194logistic regression analysis was performed to identify vari-
ables independently associated with a final diagnosis of
HF including peptides (one in each model), AF, and the
covariates age, sex, history of acute HF, myocardial infarc-
tion, chronic obstructive pulmonary disease (COPD), dia-
betes and examination variables (rales, wheezing, third heart
sound [S3], murmur, edema and elevated jugular venous
pressure [JVP]). Multivariate Cox models were used to
define variables independently prognostic for mortality
and the influence of AF on the prognostic performance of
the peptides. Model 1 included the peptide, AF and the
interaction term of AF and peptide. Models 2 and 3
additionally included age and sex and age, sex, and creati-
nine concentration of >1.6 mg/dl. A p value of <0.05 was
taken to indicate significance.Results
Baseline characteristics. Of the 1,445 patients included in
the current analyses, 557 (38.5%) had HF, and 242 (16.7%)
had AF. AF was more common in those with HF than in
those without (27.5% and 10%, respectively, p < 0.001). HF
was more common in those with AF than in those without
(63.2% and 33.6%, respectively, p < 0.001). Patient char-
acteristics are presented in Table 1. Patients with AF were
older and more likely to have elevated JVP and rales present
on enrollment.
As expected, median BNP, NT-proBNP, and MR-
proANP values in HF were significantly higher than in
non-HF cases (836 vs. 57 pg/ml, 5,171 vs. 225 pg/ml, and
421 vs. 92 pmol/l, respectively; all p< 0.001). Figure 1 shows
plasma concentrations of the 3 peptides in patients with and
without HF further divided according to presence or absence
of AF. Lowest values of all three peptides were observed in
patients with neither HF nor AF. There was a significant
increase in the levels of all 3 peptides in patients with AF
withoutHF (p< 0.001 for all 3 peptides) and a further step up
in levels in HF with or without AF (p < 0.001 for all
peptides).
Multivariable analyses indicated each peptide was the
strongest independent predictor of a final diagnosis of HF
within each model (chi-square values: 138.55 to 171.44;
p < 0.0001 for all) with additional significant predictors
consistently including male sex, previous HF, COPD, dia-
betes, and presence of rales, edema and raised JVP (Online
Tables 1a to 1d).
The utility of MR-proANP and the B type peptides
for diagnosis of HF in the presence and absence of AF was
determined by ROC analysis. Figure 2 shows ROC curves
for the diagnosis of HF in the absence (n ¼ 1,203) and
presence (n ¼ 242) of AF. In the absence of AF all three
peptides exhibited strong and similar discrimination of
HF whereas in AF all have similar and substantively
lower AUCs. Hence AF resulted in similar clear reductions
in the diagnostic power of BNP, NT-proBNP and
MR-proANP.Diagnostic test performance characteristics for ROC-
derived optimal diagnostic values of all 3 peptides in the
presence and absence of AF are displayed in Table 2 for
those with and without AF along with the performance
of values currently recommended in clinical practice (i.e.,
100 pg/ml for BNP and age-adjusted values for NT-
proBNP). The diagnostic performance of optimal values of
all 3 peptides in the absence of AF was excellent and very
similar with sensitivities exceeding 88%, specificities >79%,
positive predictive values (PPV) >68%, negative predictive
values (NPV) >92% and accuracy >82%. When peptide
thresholds derived from the non-AF group were applied to
AF patients test performance exhibited preserved sensitivity
but marked drops in specificity (from w80% down to 30%)
along with substantively reduced NPV and accuracy
(Table 2). When optimum peptide thresholds derived from
AF group data were applied to AF patients it was notable
that values were higher than those observed for the non-AF
cases and each peptide exhibited major impairment in
sensitivity (all <61%), NPV (<53%) and accuracy (<67%)
while specificity (all >73%) and PPV (>68%) were preserved
(Table 2).
Natriuretic peptides for prognosis in HF with and
without AF. Ninety-day mortality was 8.6% (124 of 1,445
patients). Mortality in those with HF without AF was
11.1%, in those with AF but no HF 11.2%, in those with
both, 12.4% and in those with neither 6.3%. Kaplan-Meier
survival curves did not differ between patients with and
without AF (data not shown). Over 90 days of follow-up,
AUCs for prediction of all-cause mortality in those with
HF were of only moderate strength for all 3 peptides and did
not differ significantly between absence (0.65, 0.60, and 0.67
for MR-ANP, BNP, and NT-proBNP, respectively ) and
presence of AF (0.66, 0.62, and 0.66, respectively) for any
marker. On multivariate analysis there was no significant
interaction between AF and any of the 3 peptide markers for
prediction of all-cause mortality (Online Tables 2a to 2c).
Discussion
Results from the BACH multinational trial demonstrate
that plasma concentrations of MR-proANP, BNP, and
NT-proBNP are elevated by AF in the absence of HF. HF
is associated with a further increase in peptide levels but, in
accord with other recent reports from cohorts with acute
breathlessness (9,10) the combination of AF and HF was
not associated with peptide levels above those seen in HF
alone (Fig. 1). This differs from previous reports of smaller
cohorts with chronic heart failure in which HF with AF was
associated with higher plasma natriuretic peptide levels than
in HF alone (20,21). The explanation for this is uncertain
but it is likely that in AF with fast heart rate (as is typical in
dyspneic AF patients presenting emergently) the onset of
acute clinical heart failure occurs at lesser degrees of
underlying left ventricular dilatation and dysfunction. That
is, increases in peptides due to the specific effects of AF may
Table 1 Patient Characteristics
Variables N
Heart Failure (n ¼ 557)
p Value*
No Heart Failure (n ¼ 888)
p Value*
Atrial Fibrillation
(n ¼ 153)
No Atrial Fibrillation
(n ¼ 404)
Atrial Fibrillation
(n ¼ 89)
No Atrial Fibrillation
(n ¼ 799)
Demographics
Age (yrs) 1,445 75.5  12.1 69.4  14.1 0.002 73.1  11.71 61.4  15.8 0.000
No. of males 90 258 0.273 49 385 0.219
Race
White 1,019 135 289 80 515
Black 361 14 103 0.000 8 236 0.000
Other 52 1 38 2 11
Recent history (% of entire cohort)
Smoking 1,402 21 103 0.005 15 251 0.005
Wheezing 1,353 27 80 0.685 17 224 0.166
Night sweats 1,313 25 69 0.844 16 164 0.610
Weight gain 1,256 43 91 0.058 9 80 0.918
Paroxysmal nocturnal dyspnea 1,316 67 175 0.672 24 167 0.302
Orthopnea 1,351 99 238 0.101 37 254 0.082
Dyspnea at rest 1,414 78 195 0.473 39 371 0.578
History variables
Arrhythmia 1,369 116 116 0.000 64 96 0.000
Asthma 1,402 6 24 0.367 12 173 0.065
CRI 1,389 42 125 0.590 9 60 0.373
Heart failure 1,402 99 259 0.784 31 155 0.001
Coronary artery disease 1,393 70 194 0.933 29 187 0.038
COPD/emphysema 1,399 35 95 0.875 33 267 0.529
Diabetes 1,426 50 163 0.114 21 193 0.876
Hyperlipidemia 1,358 51 182 0.025 26 276 0.728
Hypertension 1,419 113 316 0.425 66 505 0.051
Myocardial infarction 1,371 37 130 0.073 10 113 0.526
Pulmonary embolism 1,409 18 72 0.600 2 44 0.195
Prior CABG 1,421 18 72 0.099 6 55 0.950
Angioplasty/stent 1,409 26 80 0.539 13 80 0.176
Stroke/CVA 1,413 18 55 0.581 13 68 0.052
Pacemaker/ICD 1,421 19 86 0.020 9 42 0.065
Prosthetic valve 1,417 14 15 0.009 3 9 0.080
Examination variables (%)
Mean heart rate (beats/min) 1,445 99.4  33 85.5  20 0.0001 102.9  30 91.2  21 0.0005
Rales 1,430 97 203 0.009 28 176 0.044
S3 1,390 6 32 0.095 1 5 0.587
Murmur 1,412 38 118 0.311 15 78 0.036
Elevated JVP 1,351 68 129 0.006 12 53 0.026
Edema 1,424 101 237 0.194 31 198 0.041
Ascites 1,393 8 18 0.717 1 12 0.778
Wheezing 1,424 26 75 0.652 24 222 0.970
Values are N, mean  SD, or n. *Comparison of subjects with atrial fibrillation versus without atrial fibrillation, within the subgroups of heart failure diagnosis and no heart failure diagnosis, respectively.
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary disease; CRI ¼ chronic renal insufficiency; CVA ¼ cardiovascular accident OR cerebrovascular accident; ICD ¼ implantable
cardioverter-defibrillator; JVP ¼ jugular venous pressure; S3 ¼ third heart sound.
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195be offset by relatively less underlying ventricular impairment
than present in those with acute HF in the absence of AF.
These counterbalancing contributions to plasma peptide
levels may then result in similar average plasma peptide
concentrations as observed by ourselves and others (9,10).
This pattern may be absent in chronic, treated HF (20,21)
in which AF heart rates are lower than in acute HF.
Measures of ventricular function are not available from the
BACH cohort and investigation of this proposition must
await further study.The diagnostic performance of MR-proANP, BNP and
NT-proBNP was substantially impaired in patients with
AF. Findings are qualitatively consistent with those re-
ported by Knudsen et al from the “Breathing Not Properly”
trial which assessed the diagnostic utility of BNP in a very
similar population to that recruited in the BACH study (9).
Morello et al (10) reported elevated NTpro-BNP levels in
AF without HF, in a subgroup analysis from the PRIDE
cohort of 600 dyspneic patients. Knudsen et al reported
a fall in AUC for diagnosis of HF by BNP from 0.91
Figure 1 Box Plots
Box plots of mid-region pro-atrial natriuretic peptide (MR-proANP) (top), B-type
natriuretic peptide (BNP) (middle), and amino terminal pro-B-type natriuretic
peptide (NT-proBNP) (bottom) in patients categorized according to presence
or absence of heart failure (HF) and presence (þ) or absence () of atrial
fibrillation (AF).
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196without AF to 0.84 with AF (9). In the current report the
effect is more pronounced with a change from 0.91 to 0.76,
with very similar results observed for MR-ANP and NT-
proBNP. It is likely this difference reflects differences in
the method used to diagnose AF. In the Knudsen analysis
patients with both a medical history of AF as well as those
with AF on electrocardiogram (ECG) at recruitment were
included in analyses as AF patients. However, of 292
patients classified as having permanent or paroxysmal AF,
256 were so classified on the strength of a medical historyof AF and of these only 122 presented with ECG-
documented AF at recruitment in the ED. Therefore
about half (46%) of patients labeled as “AF” for the
purposes of analyses were not in AF at the time of blood
sampling. As the effect of the arrhythmia is dynamic with
NP levels falling promptly with conversion from AF to
sinus rhythm (11,22–25) it is likely this analysis significantly
underestimated the extent to which current AF confounds
the diagnosis of HF by NPs. The current analysis classifies
patients purely according to the rhythm observed on ECG
at recruitment.
In AF, loss of atrioventricular synchrony may result in
impaired diastolic filling, reduced stroke volume, increased
mean diastolic atrial pressure, and reductions in cardiac
output (26–28). However, AF also clearly increases plasma
levels of NPs in the absence of frank HF (9–13). BNP and
NT-proBNP are produced and co-stored in atrial granules
along with ANP and amino-terminal ANP (29–31). Rapid
AF with its variable cycle length and ventricular filling
times may lead to chaotic microregional variations in atrial
cardiomyocyte strain potentially distorting and stretch-
ing local populations of cardiomyocytes triggering NP
release in the absence of increased mean intra-cardiac or
transmural distending pressures (32). Histopathology of
atrial tissue in AF reveals inflammatory, hypertrophic
and fibrotic changes any and all of which may promote
increased NP expression and release (33). This is consis-
tent with the finding of increased pro-BNP and pro-ANP
messenger RNA in atrial tissue from patients with AF
(34). Together these effects raise plasma NP levels in
AF and weaken their performance in the diagnosis of
acute HF.
The ability of physicians to diagnose HF may be impaired
in the presence of AF which can render assessment of
physical signs such as jugular venous distension and cardiac
sounds more difficult. Therefore the “gold standard”
employed to adjudicate the final diagnosis may have been
less reliable in AF.
Using peptide thresholds derived from non-AF patients
in AF patients results in preserved sensitivity but re-
duced specificity. Even values optimized for AF cannot
match test performance seen in the non AF population
(Table 2). However, it is important to note that in the
BACH population (i.e., people presenting with breath-
lessness to the ED in the absence of an obvious
noncardiac cause) two thirds of cases with AF had con-
current HF. In the “Breathing Not Properly” cohort the
corresponding figure was 75% and in “PRIDE” 79%
(7,10). Therefore in patients presenting with acute
dyspnea and AF, HF should be presumed present until
proven absent as the “false positive” group with elevated
NP levels in the absence of HF will comprise only
a minority of these patients.
Prognosis. MR-proANP was independently prognostic
in the BACH cohort but did not perform any more
strongly than BNP or NT-proBNP and gave weaker
Figure 2 Receiver-Operator Curves for Diagnosis of HF in the Absence (n ¼ 1,203) and Presence (n ¼ 242) of AF
(Left) Without AF areas under the curve (AUC) were 0.899, 0.912, and 0.893 for MR-proANP, BNP, and NT-proBNP, respectively. (Right) In AF corresponding area under the
curves AUCs were 0.702, 0.754, and 0.724, respectively.
Table 2 Diagnostic Test Performance
Cutoff Sensitivity Specificity PPV NPV Accuracy Positive LR Negative LR
MR-proANP
AF
210 89.5 31.5 69.0 63.6 68.0 1.31 0.33
370* 56.6 73.0 78.2 49.6 62.7 2.10 0.59
No AF
210* 87.3 80.7 69.4 92.7 82.9 4.52 0.16
370 57.1 92.2 78.7 81.1 80.5 7.35 0.47
BNP
AF
100 98.7 12.4 65.9 84.6 66.9 1.13 0.11
220 88.9 32.6 69.4 63.0 68.2 1.32 0.34
490* 58.2 80.9 84.0 52.9 66.5 3.05 0.52
No AF
100 94.3 62.7 56.0 95.6 73.3 2.53 0.09
220* 88.1 81.3 70.4 93.1 83.6 4.72 0.15
490 71.2 92.2 82.2 86.4 85.2 9.17 0.31
NT-proBNP
AF
1,075 95.4 25.8 68.6 76.7 69.6 1.29 0.18
3,460* 60.9 73.0 79.3 52.4 65.4 2.26 0.53
Age-specific 88.1 32.6 68.9 61.7 67.5 1.31 0.37
No AF
1,075* 88.5 79.0 68.1 93.1 82.2 4.21 0.15
3,460 64.5 90.9 78.2 83.5 82.0 7.08 0.39
Age-specific 85.8 78.9 67.3 91.6 81.2 4.06 0.18
Diagnostic test performance with atrial fibrillation (AF) or without (no AF) AF of optimal peptide thresholds (cutoff) derived from AUCs for each
peptide separately for AF and non-AF patients. Cutoffs were determined by maximizing the product of sensitivity and specificity. Optimal peptide
thresholds in the absence of AF (n ¼ 1,203) were 210, 220, and 1075 pg/ml for MR-proANP, BNP, and NTproBNP, respectively. In AF (n ¼ 242),
corresponding values were 370, 490, and 3,460 pg/ml, respectively. The test performance of values optimal in AF and no AF are listed for both
conditions. Additional values listed for BNP (top row) and NTproBNP (bottom row) are those commonly used in clinical practice (i.e., 100 pg/ml for
BNP) and age-specific values for NtproBNp (i.e., 450 pg/ml for patients <50 years of age, 900 pg/ml for those >50 to <75 years of age, and 1,800
pg/ml for those older than 75 years of age). *Optimal value for the corresponding condition. For MR-proANP and NTproBNP, optimal values for non-
AF and AF are listed at the top and in the second row of each panel and in the second and third rows for BNP.
LR ¼ likelihood ratio.
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198prediction of 90 day mortality than that previously re-
ported for MR-pro adrenomedullin in the BACH cohort
(15). Our findings are consistent with previous reports
suggesting the prognostic value of plasma NPs in acute
HF is moderate (i.e., less than their diagnostic power) but
is not diminished by AF although the optimal values for
prognostic purposes will be higher than that in HF
patients without AF. We detected no interaction between
AF and NPs with respect to prediction of 90-day all-cause
mortality.
Conclusions
MR-proANP has been demonstrated to be non-inferior to
BNP and NT-proBNP for the diagnosis of HF in newly
breathless patients (15). We report, as in the case of the
B-type cardiac natriuretic peptides, the utility of MR-
proANP for diagnosis of HF is impaired in the presence
of AF. We did not find any significant effect of AF on the
prognostic performance of any marker.
These findings indicate the need to consider different
(i.e., higher) diagnostic threshold values for natriuretic
peptides in the presence of AF and mandate a continued
search for markers which reflect the presence of HF without
confounding by AF.
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